Sudden cardiac death (SCD) secondary to arrhythmia remains a risk in those with dilated cardiomyopathy (DCM), an implantable cardiac defibrillator (ICD) is an effective strategy to prevent SCD. Current guidelines recommend selection for ICD based on ejection fraction (EF) less than 35%, however, most SCD occurs in those with EF>35%. Although meta-analysis has demonstrated a survival benefit for primary prevention ICD in DCM, no randomised trial has shown a significant reduction in overall mortality including the most recent 'Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heat Failure on Mortality' study. Clearly, a more sophisticated selection strategy is required. Cardiac MRI (CMR) is an ideal non-invasive imaging technique which allows calculation of EF as well as tissue characterisation with gadolinium contrast, parametric mapping and feature tracking. Late gadolinium enhancement detects mid-wall fibrosis in approximately 30% of those with DCM, three meta-analyses have demonstrated an association between fibrosis in DCM and SCD, and those without fibrosis are at low risk of SCD. T1 mapping and extracellular volume (ECV) calculation are methods of demonstrating diffuse fibrosis in the myocardium. Raised ECV and native T1 have been associated with worse outcomes but the relationship to SCD has not been well studied. Undoubtedly, more research is required but CMR has several tools which offer incremental value above EF to improve risk stratification and consequent outcomes and resource utilisation in those with DCM.
AbsTRACT
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InTRoduCTIon
Approximately 30% of those with dilated cardiomyopathy (DCM) will suffer sudden cardiac death (SCD). 1 The implantable cardiac defibrillator (ICD) is effective for primary prevention of arrhythmic SCD and is recommended in symptomatic heart failure (New York Heart Association (NYHA) II-III) and left ventricular ejection fraction (LVEF) of less than 35% regardless of aetiology. 2 However, the majority of SCD occurs in those without severe left ventricular systolic dysfunction (LVSD) 3 who have no indication for primary prevention ICD. Significant numbers of those with an ICD will never receive appropriate therapy 4 while being exposed to the non-negligible risk of complications which occur in 9.1% of patients. 5 Even with contemporary ICD programming inappropriate shocks occur in 3% of patients and have significant impact on quality of life. 6 Consequently, current risk stratification methods could be improved.
The broad issue of non-invasive imaging markers associated with SCD has recently been reviewed. 7 This review will focus on the role of cardiac MR (CMR) and its potential for improving risk stratification in DCM.
LVEF: ThE EsTAbLIshEd RIsk sTRATIFICATIon METhod
An ejection fraction (EF) <30% confers the most adverse prognosis 8 but the absolute number of people who suffer SCD is substantially higher in those with EF>35% due to a greater number of those with DCM having an EF>35%. 3 LVEF is clearly a marker of disease severity but is neither a specific nor sensitive marker for SCD. When selecting according to LVEF, no randomised trial has shown a significant mortality reduction with primary prevention ICD in DCM, 4 9-12 despite ICD implantation being effective in preventing SCD. 4 12 A summary of the trials to date is seen in table 1.
Meta-analysis of these trials demonstrated a significant survival benefit for primary prevention ICD in patients with DCM and severe LVSD 13 ; findings confirmed by a recent meta-analysis 14 including DANISH trial data. The fact that survival benefit can be observed only by pooling data indicates that we need to improve patient selection by increasing our ability to discriminate between risk of SCD and risk of death from heart failure or non-cardiovascular causes. Subgroup analysis in the DANISH trial showed that ICDs provided a significant survival benefit to patients younger than 70 years old, not because they had a higher risk of SCD without the ICD but because they had a lower risk of non-sudden death, therefore their sudden versus non-sudden death ratio was higher.
Cardiac resynchronisation therapy (CRT) adds further complexity. No clinical trial has established that the addition of ICD to CRT (CRT-D) improves survival beyond CRT alone (CRT-P) 15 ; findings confirmed by the CRT subgroup of the DANISH trial (645 patients, HR 0.91 and p=0.73 for CRT-D vs CRT-P). 12 An observational study of 5307 patients demonstrated that CRT-D was associated with lower mortality than CRT-P only among those with ischaemic cardiomyopathy, rather than DCM. 16 This may reflect that patients with DCM usually respond better to CRT 17 and echocardiographic response to CRT is associated with lower incidence of ventricular arrhythmia. 18 As a more sophisticated risk stratification method is developed for DCM it should also aim to provide clearer recommendations regarding CRT-D versus CRT-P.
ThE EMERgIng RIsk sTRATIFICATIon METhod: LATE gAdoLInIuM EnhAnCEMEnT
CMR with administration of gadolinium-based contrast agent allows non-invasive evaluation of localised cardiac replacement fibrosis, seen when a collagen matrix is laid down in response to myocyte damage, necrosis and/or apoptosis, leading to a distinct myocardial scar (Figure 1 ). Gadolinium shortens the T1 relaxation time of the scarred tissue which consequently appears bright when the inversion recovery sequence is set to null normal myocardium. 19 The presence of myocardial replacement fibrosis seen on late gadolinium enhancement (LGE)-CMR has been shown to correlate with histological areas of plexiform fibrosis. 20 21 The most typical pattern seen in DCM is mid-wall fibrosis (MWF) but other patterns are seen; 30%-40% have LGE. 22 23 Beyond diagnosis, fibrosis in DCM can be used to predict prognosis.
Review
Assomull et al 24 conducted the first study demonstrating the association of fibrosis with adverse prognosis in DCM. Thirty-five per cent of 101 patients studied had MWF with LGE presence being associated with all-cause mortality and hospital admission for cardiovascular causes (HR 3.4; 95% CI 1.4 to 8.7, p=0.01). Those with LGE were more likely to have SCD/ventricular tachycardia (VT) although overall event rates were low. Subsequently, Iles et al 25 evaluated whether LGE presence predicted appropriate ICD shock in patients who satisfied primary prevention ICD criteria; 51% of those with DCM had LGE. No ICD discharges were seen in those without LGE compared with a 29% discharge rate in those with LGE (p<0.01). A further study 21 demonstrated a significant association between MWF and all-cause mortality (p<0.001) even after adjustment for EF; 29.6% of those with fibrosis reached the arrhythmic end points of SCD or aborted SCD versus 7% of those without fibrosis (p<0.001). Recently, the question of whether LGE signifies risk in those with DCM and EF>40% was studied. 26 A total of 399 patients were enrolled, 25% had MWF, mean EF was 49% and median follow-up was 4.6 years. The composite primary end point of SCD or aborted SCD occurred in 18 (17.8%) patients with LGE and 7 (2.3%) patients without LGE (p=<0.0001). This significance continued even after adjustment for potential confounders such as age, NYHA class and LVEF (HR 9.3). MWF had just a borderline association with all-cause mortality (p=0.056), suggesting that LGE might be a specific marker of ventricular arrhythmia, and therefore could identify patients with a higher risk of SCD rather than death from other causes. Several other smaller, often single-centre studies with diverse end points have been studied and synthesised into three meta-analyses delivering a consistent message 23 27 28 (table 2) . The largest and most recent meta-analysis 23 confirmed that in contrast to LVEF, LGE was significantly and strongly associated with the arrhythmic end point of SCD, sustained VT or appropriate ICD therapy (pooled OR 4.3, 95% CI 3.3 to 5.8, p=0.001). Moreover, the association between LGE and ventricular arrhythmias was observed both in studies with mean LVEF<35% (OR 4.2, 95% CI 2.4 to 7.2, p=<0.001) and in studies with mean LVEF>35% (OR 5.2, 95% CI 3.4 to 7.9, p=<0.001).
LGE could also be useful in the subgroup of those who meet criteria for CRT. A recent observational study including 252 patients with DCM and CRT found that CRT-D provided survival benefit over CRT-P only in those with LGE. 29 Additionally, absence of LGE is associated with greater CRT response. 30 These studies considered the dichotomous variable LGE presence versus LGE absence. While it may be considered intuitive it is yet unclear whether LGE quantification can further improve risk stratification. LGE can be quantified using a variety of signal thresholding methods but as yet there is no consensus on the most robust and reproducible method to use. One study using the 2 SD and full width at half maximum methods found that those with >6.1% myocardium affected by LGE had the greatest risk of major adverse cardiac events. 31 Conversely, another study 26 () concluded that there is no linear increase in SCD risk as LGE extent increases; the greatest increase in risk of SCD occurs between no LGE and those with 2.5% LGE.
LGE presence versus absence is a simple, reproducible and pragmatic parameter. The important message being that patients with DCM without LGE have low risk of ventricular arrhythmia or SCD.
T1 MAppIng And ECV quAnTIFICATIon
Endomyocardial biopsy is currently the gold standard for detection of diffuse fibrosis but carries inherent risk and has limited diagnostic yield. CMR with T1 mapping and extracellular volume (ECV) calculation allows one to demonstrate diffuse fibrosis in a non-invasive manner and unlike LGE does not rely on local differences in image contrast (Figure 1) . In a T1 map, the T1 value is encoded in each pixel and corresponds to the T1 relaxation time constant of the corresponding myocardial voxel. T1 maps can be created both before (native T1) and after gadolinium contrast and generally in DCM, native T1 values increase and after contrast T1 values get shorter. 19 32 By comparing signal intensity changes (as a function of contrast concentration changes) in the extracellular compartment with those in the blood pool and integrating the available blood volume distribution (1 haematocrit (HCT)) one can calculate the partition coefficient lambda which in turn allows estimation of the myocardial extracellular volume space using the formula ECV=(1−HCT×lambda).
Review
Calculated ECV is comparable with histological collagen volume fraction in DCM and increased ECV and native T1 is seen in those with DCM compared with controls. 33 Puntmann et al 34 found that in those with cardiomyopathy native T1 was Review longer (p<0.01), post contrast T1 was shorter (p<0.01) and ECV was significantly higher (p<0.01). Following ROC analysis native T1 was found to be the best independent discriminator between healthy and diseased myocardium with a specificity of 97% and sensitivity of 100%. Currently, T1 mapping is predominantly used in research settings and it is recommended that each centre establishes their own reference ranges given the potential between scanner and vendor variation related in part to field strength, sequence and acquisition parameters. 35 ECV has generally less variability than native T1 values as the acquisition of precontrast and postcontrast T1 cancels out factors affecting the precision of native T1 when acquired in isolation, specifically the total volume (fraction) of possible contrast distribution, degree of patient hydration and degree of renal impairment. Normal values have been published by multiple groups for T1 and ECV at both 1.5T and 3T field strength and have found to be consistent with surprisingly little interobserver differences and good test-retest variability. 36 37 There are also ongoing largescale standardisation and validation studies including phantom exchange projects. 38 Do T1 mapping techniques and ECV parallel findings appear in LGE literature?
Prognostic data relating to T1 mapping and ECV lag behind that of LGE and have not been as well validated. However, some studies have been undertaken and the volume of literature continues to expand.
Wong et al 39 examined those with both ischaemic and non-ischaemic cardiomyopathy and found that ECV>28.5% was significantly associated with all-cause mortality (HR 1.55, 95% CI 1.27 to 1.88 for every 3% increase in ECV). Findings supported in a later study by the same group 40 who calculated ECV across a range of EFs; raised ECV was associated with hospitalisation for heart failure, death or both. A study of 89 patients with non-ischaemic cardiomyopathy found that an ECV>32% was a prognostic predictor of mortality beyond echo parameters and that ECV was raised compared with controls even in those without LGE. 41 In those with DCM, native T1 was significantly associated with all-cause mortality independent of both LVEF<35% and LGE presence. 42 Indeed, higher T1 values outperformed presence of LGE in predicting adverse outcomes. The association between diffuse fibrosis detected by CMR and SCD in DCM has not yet been widely analysed. One study 43 has scrutinised the link between T1 mapping and ventricular arrhythmia in patients with ICD implanted for primary or secondary prevention. Subgroup analysis showed that in the 59 non-ischaemic patients (53 DCM, 5 hypertrophic cardiomyopathy and 1 sarcoidosis), native septal T1 was the only independent predictor of appropriate ICD therapies (HR 1.12 every 10 ms increase, p<0.01) and of the composite end point of appropriate ICD therapies or death from any cause (HR 1.1 every 10 ms increase, p<0.01). However, ECV was not associated with the end points analysed.
Native T1 mapping has the potential to negate the need for gadolinium-based contrast examinations in selected patients. However, one particular T1 or ECV value can indicate a variety of cardiomyopathies and pseudonormalisation can occur. It seems unlikely that T1 mapping or ECV will be used as a single diagnostic or prognostic parameter and should be used as part of a multiparametric approach.
sTRAIn IMAgIng
EF describes global myocardial function but is an imprecise measure of regional myocardial dysfunction; strain imaging, on the contrary, characterises regional deformation of an area of myocardium and can detect early myocardial dysfunction before EF decreases. Substantial echocardiography-based data have accumulated highlighting the value of strain, specifically global longitudinal strain (GLS), in predicting outcome. One multimodality study of those with DCM found that GLS>−8.3% calculated by 2D echocardiography combined with positive LGE on CMR heralded the most adverse prognosis beyond LVEF. 44 CMR assessment of myocardial deformation has been available since the 1980s initially requiring additional (time-consuming) sequences and dedicated postprocessing technologies. Various conceptual approaches based on myocardial tagging or displacement encoding with stimulated echoes were developed but did not penetrate into daily clinical routine. This changed with the arrival of feature tracking technology which is analogous to echocardiographic speckle tracking which tracks tissue boundaries over time rather than an intramyocardial point and can be applied as part of a standard CMR protocol. 45 Buss et al 46 conducted a study of 210 patients with DCM who had CMR feature tracking-based strain calculated. They found that a GLS>−12.5% was predictive of a combined primary end point of cardiac death, heart transplantation and appropriate ICD shock due to VT or fibrillation. In univariate analysis, GLS was predictive of the primary end point (HR 1.33, 95% CI 1.21 to 1.47, p<0.0001). After multivariate analysis, GLS was predictive of the primary end point above LVEF and BNP (HR 1.27, 95% CI 1.05 to 1.52, p<0.02). The study also suggested that those with preserved GLS had a good prognosis irrespective of EF and LGE presence. A further study 47 studied a mixed aetiology cohort of 1012 patients and EF<50%. It was found that after adjustment for EF and LGE every 1% decrease in GLS conferred an 89.1% increased risk of death (HR 1.891 per %, p<0.001). When limiting the analysis to those with non-ischaemic cardiomyopathy GLS was an independent risk factor for death beyond LGE and EF (HR 2.01 per %, p<0.001). Preserved GLS also identified patients with lower risk among those with LGE.
GLS calculation by CMR feature tracking has yet to be widely used in clinical practice. Normal values have been published 48 but have yet to be validated on a large scale and cut-offs for specific disease states are yet to be established. Strain imaging in general is hampered by high naturally occurring variation and high test-retest variability. CMR feature tracking specifically is limited by lower temporal resolution, meaning that strain values may be underestimated. Certainly, more studies are needed using CMR-based methods of calculating strain to determine the exact prognostic role of GLS in SCD prediction in patients with DCM.
FuTuRE dIRECTIons
Further research should focus on (1) evaluating CMR parameters that could improve risk stratification of SCD in DCM beyond LGE and (2) assessing if CMR-guided ICD implantation can improve clinical outcomes in DCM. A recent observational study 49 suggests that among patients with DCM and LVEF<35%, ICD implantation was associated with a reduction in mortality only among those with LGE. An even more recent publication following 874 patients over a median of 4.9 years highlighted the increased risk of septal and lateral mid-wall LGE but indicated that the incremental value of LGE extent beyond the presence of LGE was small. 50 Randomised trials are needed to assess whether ICD provides prognostic advantage to patients with DCM and severe LVSD but no LGE; if no benefit is found and only those with LVEF<35% and LGE were given an ICD, the number needed to treat to save one life would be Review significantly reduced. Subsequent randomised trials should also explore whether patients with LGE and EF>35% could also benefit from primary prevention ICD implantation. This latter aspect is currently being evaluated in the CMR-Guide trial (NCT trial number NCT01918215); however, this study will include a mixed aetiology cohort so will not be specific for DCM.
ConCLusIon
Current clinically applied risk stratification for ventricular arrhythmia and SCD death in DCM purely based on EF as the single imaging parameter remains inadequate. CMR allows a complete structural and functional analysis of the heart: some CMR parameters, such as LGE, have already shown a consistent and strong association with ventricular arrhythmias and sudden death. Others need to be further investigated for this specific outcome. Future application of a multiparametric approach holds promise to improve and personalise the arrhythmic risk of patients with DCM.
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